1YR企业会员
| 英文名称 | 中文名称 | CAS |
|---|---|---|
| Anacardic acid | 漆树酸 | 16611-84-0 |
| BEZ235 | NVP-BEZ235 | 915019-65-7 |
| API-1 | 4-Amino-5,6,7,8-tetrahydro-5-oxo-8-(β-D-ribofuranosyl)pyrido[2,3-d]pyrimidine-6-carboxamide | 36707-00-3 |
| PI-3065 | PI-3065 | 955977-50-1 |
| Serabelisib | [6-(2-氨基-5-苯并恶唑基)咪唑并[1,2-A]吡啶-3-基]-4-吗啉基甲酮 | 1268454-23-4 |
| Rapamycin | 雷帕霉素 | 53123-88-9 |
| Presatovir | GS-5806 | 1353625-73-6 |
| Lifirafenib | LIFIRAFENIB | 1446090-79-4 |
| CU-T12-9 | CU-T12-9 | 1821387-73-8 |
| YKL-05-099 | 化合物YKL-05-099 | 1936529-65-5 |
| DDD107498 | 1469439-69-7 | 1469439-69-7 |
| Givinostat (ITF2357) | N-[4-[(羟基氨基)羰基]苯基]氨基甲酸 [6-[(二乙基氨基)甲基]-2-萘基]甲酯盐酸盐水合物 | 732302-99-7 |
| Isoxazole 9 (ISX-9) | ISX 9 | 832115-62-5 |
| AZD5363 | 4-氨基-N-[(1S)-1-(4-氯苯基)-3-羟基丙基]-1-(7H-吡咯并[2,3-D]嘧啶-4-基)-4-哌啶甲酰胺 | 1143532-39-1 |
| GSK-J4 Hydrochloride | GSK-J4 盐酸盐 | 1797983-09-5 |
| Liproxstatin-1 | 利普司他丁-1 | 950455-15-9 |
| RK-33 | RK-33 | 1070773-09-9 |
| PF-9366 | PF-9366 | 72882-78-1 |
| CM-272 | 化合物CM-272 | 1846570-31-7 |
| Veliparib | 维利帕尼 | 912444-00-9 |
| AZ 628 | AZ 628 | 878739-06-1 |
| MRT67307 | N-[3-[[5-环丙基-2-[[3-(4-吗啉基甲基)苯基]氨基]-4-嘧啶基]氨基]丙基]环丁烷甲酰胺 | 1190378-57-4 |
| UNC0638 | UNC0638 | 1255580-76-7 |
| AR7 | CS-2649 | 80306-38-3 |
| HTH-01-015 | HTH-01-015 | 1613724-42-7 |
| BAM 15 | CS-2890 | 210302-17-3 |
| 1,3-Benzenediol, 4-[1-(2-propenyl)-7-(trifluoromethyl)-1H-indazol-3-yl]- | 1,3-Benzenediol, 4-[1-(2-propenyl)-7-(trifluoromethyl)-1H-indazol-3-yl]- | 669764-18-5 |
| Pyrimorph | 丁吡吗啉 | 868390-90-3 |
| R-10015 | METHYL 2-(1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDIN-4-YL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLATE | 2097938-51-5 |
| TK216 | TK216 | 1903783-48-1 |
| VPC-80051 | 1H-Indazole-3-carboxamide, N-[1-(3,4-difluorophenyl)ethyl]- | 877969-69-2 |
| Losmapimod | Losmapimod (GW856553X) | 585543-15-3 |
| MM-102 | MM-102 | 1417329-24-8 |
| 1-(2,4-Dichlorophenyl)-N-1-piperidinyl-4-[[(1-pyrrolidinylsulfonyl)amino]methyl]-5-[5-[2-[4-(trifluoromethyl)phenyl]ethynyl]-2-thienyl]-1H-pyrazole-3-carboxamide | 1-(2,4-二氯苯基)-N-1-哌啶基-4-[[(1-吡咯烷基磺酰基)氨基]甲基]-5-[5-[2-[4-(三氟甲基)苯基]乙炔基]-2-噻吩基]-1H-吡唑-3-甲酰胺 | 1429239-98-4 |
| Aldose reductase-IN-1 | AT-001 | 1355612-71-3 |
| MK2-IN-3 | 2-[2-(3-quinolyl)-4-pyridyl]-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one | 724711-21-1 |
| PythiDC | 化合物PYTHIDC | 1821370-71-1 |
| Mizagliflozin (KWA 0711) | Mizagliflozin | 666843-10-3 |
| PRE-084 hydrochloride | 1-苯基环己烷羧酸 2-(4-吗啉基)乙基酯盐酸盐 | 75136-54-8 |
| AnsamitocinP-3 | 安丝菌素 P 3 | 66584-72-3 |
| UPF 1069 | 5-(2-氧代-2-苯基乙氧基)-1(2H)-异喹啉酮 | 1048371-03-4 |
| A66 | A66 | 1166227-08-2 |
| HDAC6 inhibitor | HDAC6 Inhibitor | 1045792-66-2 |
| NIBR-0213 | NIBR 0213 | 1233332-14-3 |
| Vactosertib (TEW-7197) | EW-7197 | 1352608-82-2 |
| MBQ-167 | MBQ 167;MBQ167 | 2097938-73-1 |
| WYC-209 | 4,5-二(羟甲基)-2-苯基-1H-咪唑 | 2131803-90-0 |
| FMK | FMK | 821794-92-7 |
| KU-60019 | KU-60019 | 925701-49-1 |
| VE-821 | 3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-吡嗪甲酰胺 | 1232410-49-9 |
| DCC-2036 | N-[3-叔丁基-1-(喹啉-6-基)-1H-吡唑-5-基]-N'-[2-氟-4-[(2-(甲基氨基甲酰基)吡啶-4-基)氧]苯基]脲 | 1020172-07-9 |
| A-674563 | A-674563 | 552325-73-2 |
| BGT226 (NVP-BGT226) maleate | NVP-BGT226 | 1245537-68-1 |
| BYL719 | 阿培利司 | 1217486-61-7 |
| GSK2636771 | GSK2636771 | 1372540-25-4 |
| GDC-0068 | 帕他色替 | 1001264-89-6 |
| HS-173 | HS-173 | 1276110-06-5 |
| Elacestrant dihydrochloride | RAD-1901 | 1349723-93-8 |
| VPS34 inhibitor 1 (Compound 19) | VPS34 | 1383716-46-8 |
| PF-06726304 | PF-06726304 | 1616287-82-1 |
| RY785 | 化合物RY785 | 689297-68-5 |
| BI-1347 | BI-1347 | 2163056-91-3 |
| RU-301 | RU-301 | 1110873-99-8 |
| Tm2-115 | TM2-115 | 1197196-47-6 |
| Nilotinib (AMN-107) | 尼罗替尼 | 641571-10-0 |
| VX-150 | N-[1,2-二氢-2-氧代-1-[(膦酰氧基)甲基]-4-吡啶基]-2-(4-氟-2-甲基苯氧基)-4-(三氟甲基)苯甲酰胺 | 1793080-72-4 |
| CU-CPT-8m | CPD1578 | 125079-83-6 |
| Bosutinib (SKI-606) | 伯舒替尼 | 380843-75-4 |
| BMPsignalingagonistsb4 | SB 4 | 100874-08-6 |
| UT-34 | UT-34 | 2168525-92-4 |
| DTHIB | Urea, N-(4-chloro-3-nitrophenyl)-N'-(4-fluorophenyl)- | 897326-30-6 |
| Bardoxolone | 2-氰基-3,12-二氧代齐墩果-1,9-二烯-28-酸 | 218600-44-3 |
| PS 48 | (Z)-5-(4-氯苯基)-3-苯基戊-2-烯酸 | 1180676-32-7 |
| XL765 | XL765 | 1349796-36-6 |
| GSK-J1 | N-[2-(2-吡啶基)-6-(1,2,4,5-四氢-3H-3-苯并氮杂卓-3-基)-4-嘧啶基]-BETA-丙氨酸 | 1373422-53-7 |
| IPI-3063 | 化合物IPI-3063 | 1425043-73-7 |
| SJ000291942 | SJ000291942 | 425613-09-8 |
| NI 42 | NI-42 | 1884640-99-6 |
| Go 6983 | 3-[1-[3-(二甲基氨基)丙基]-5-甲氧基-1H-吲哚-3-基]-4-(1H-吲哚-3-基)-1H-吡咯-2,5-二酮 | 133053-19-7 |
| Sirtinol | 2-[[(2-羟基-1-萘基)亚甲基]氨基]-N-(1-苯基乙基)苯甲酰胺 | 410536-97-9 |
| MK-4827 (Niraparib) | 尼拉帕尼 | 1038915-60-4 |
| TCS JNK 6o | JNK INHIBITOR VIII (TCS JNK 6O) | 894804-07-0 |
| IRAK inhibitor 1 | 环巴胺抑制剂 1 | 1042224-63-4 |
| ICA-105574 | 化合物ICA-105574 | 316146-57-3 |
| CBL0137 | 1,1'-(9-(2-(异丙基氨基)乙基)-9H-咔唑-3,6-二基)双乙烷-1-酮 | 1197996-80-7 |
| Takinib | 1111556-37-6 | 1111556-37-6 |
| HS-1793 | 化合物HS-1793 | 927885-00-5 |
| SU5204 | su5204 | 186611-11-0 |
| MRT68921 HCl | 2080306-21-2 | 2080306-21-2 |
| Enzastaurin (LY317615) | 恩扎妥林 | 170364-57-5 |
| Sotrastaurin | 3-(1H-吲哚-3-基)-4-[2-(4-甲基哌嗪-1-基)喹唑啉-4-基]吡咯-2,5-二酮 | 425637-18-9 |
| Thiazovivin | THIAZOVIVIN | 1226056-71-8 |
| INK-128 | 3-(2-氨基-5-苯并恶唑基)-1-(1-甲基乙基)-1H-吡唑并[3,4-D]嘧啶-4-胺 | 1224844-38-5 |
| A-443654 | (ALPHAS)-ALPHA-[[[5-(3-甲基-1H-吲唑-5-基)-3-吡啶基]氧基]甲基]-(S)-1H-吲哚-3-乙胺 | 552325-16-3 |
| IKK-16 (IKK Inhibitor VII) | IKK-16 | 873225-46-8 |
| WZ 4003 | WZ4003 | 1214265-58-3 |
| GSK106 hydrochloride | GSK106 (hydrochloride) | 1652591-82-6 |
| ML385 | ML385 | 846557-71-9 |
| WM 1119 | 化合物WM-1119 | 2055397-28-7 |
| LY-2940094 | BTRX-246040 | 1307245-86-8 |
联系方式
